Anixa Biosciences Inc (NASDAQ:ANIX) Director Acquires $30,800.00 in Stock

Anixa Biosciences Inc (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. acquired 10,000 shares of Anixa Biosciences stock in a transaction dated Thursday, July 31st. The shares were purchased at an average price of $3.08 per share, for a total transaction of $30,800.00. Following the completion of the transaction, the director directly owned 953,334 shares in the company, valued at approximately $2,936,268.72. The trade was a 1.06% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Anixa Biosciences Trading Up 8.3%

ANIX opened at $3.26 on Tuesday. The company has a market cap of $105.00 million, a P/E ratio of -8.58 and a beta of 0.43. Anixa Biosciences Inc has a 12 month low of $2.07 and a 12 month high of $4.20. The business’s 50-day moving average price is $3.21 and its 200-day moving average price is $2.96.

Anixa Biosciences (NASDAQ:ANIX) last issued its earnings results on Tuesday, June 3rd. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. Equities research analysts forecast that Anixa Biosciences Inc will post -0.41 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ANIX. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a research note on Tuesday, June 10th. Wall Street Zen raised shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, June 6th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $9.00.

Institutional Trading of Anixa Biosciences

Several large investors have recently modified their holdings of the business. Private Advisor Group LLC bought a new position in Anixa Biosciences during the 1st quarter valued at approximately $35,000. Millennium Management LLC purchased a new position in shares of Anixa Biosciences during the fourth quarter valued at approximately $26,000. Focus Partners Wealth bought a new position in shares of Anixa Biosciences during the fourth quarter valued at approximately $162,000. Jane Street Group LLC purchased a new stake in Anixa Biosciences in the fourth quarter worth $67,000. Finally, Renaissance Technologies LLC lifted its stake in Anixa Biosciences by 36.5% in the fourth quarter. Renaissance Technologies LLC now owns 14,573 shares of the company’s stock worth $34,000 after acquiring an additional 3,900 shares during the period. 29.13% of the stock is owned by institutional investors.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.